Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.

Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a computer implemented method of image processing comprising, upon receiving of first and second images from an imaging unit, the first and second images being respectively associated with first and second rotational changes between a reference orientation and the orientations of the first and second images: processing data representative of the first image and of the second image to compensate the first and second rotational changes between the reference orientation and the respective orientations of the first and second images, thereby obtaining first and second corrected images; processing the first corrected image to detect distinctive keypoints within a fronto-parallel strip of the first corrected image; searching keypoints in the second corrected image corresponding to the detected keypoints, and estimating a geometric transformation between the first and second images based on matching the keypoints in the first and the second corrected images.

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Abstract: A lighting system is disclosed. The lighting system comprises at least one light source comprising a light emitting diode (LED) and one or more phosphors optically coupled to the LED to convert at least a portion of original light emitted by the LED to provide a modified LED light having a first predetermined spectral output, and an optical material that is optically coupled to at least a portion of a surface of a light guide plate and optically coupled to receive at least a portion of the modified LED light and to convert at least a portion of the modified LED light to at least one predetermined wavelength to provide modified light having a second predetermined spectral output, wherein the optical material comprises one or more types of quantum confined semiconductor nanoparticle. A device including a lighting system is also disclosed.

Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.

Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.

Abstract: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.

Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.

Abstract: The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinolone and baclofen and/or acamprosate.

Abstract: A method for depth mapping includes acquiring first depth data with respect to an object using a first depth mapping technique and providing first candidate depth coordinates for a plurality of pixels, and acquiring second depth data with respect to the object using a second depth mapping technique, different from the first depth mapping technique, and providing second candidate depth coordinates for the plurality of pixels. A weighted voting process is applied to the first and second depth data in order to select one of the candidate depth coordinates at each pixel. A depth map of the object is output, including the selected one of the candidate depth coordinates at each pixel.

Abstract: Systems and methods disclosed herein relate to assigning dynamic eye-gaze dwell-times. Dynamic dwell-times may be tailored to the individual user. For example, a dynamic dwell-time system may be configured to receive data from the user, such as the duration of time the user takes to execute certain actions within applications (e.g., read a word suggestion before actually selecting it). The dynamic dwell-time system may also prevent users from making unintended selections by providing different dwell times for different buttons. Specifically, on a user interface, longer dwell times may be established for the critical keys (e.g., “close” program key, “send” key, word suggestions, and the like) and shorter dwell times may be established for the less critical keys (e.g., individual character keys on a virtual keyboard, spacebar, backspace, and the like).

Abstract: A method for providing an output image, the method includes: determining an importance value for each input pixels out of multiple input pixels of an input image; applying on each of the multiple input pixels a conversion process that is responsive to the importance value of the input pixel to provide multiple output pixels that form the output image; wherein the input image differs from the output image.